Houston cell therapy company launches second-phase clinical trial

fighting cancer

March Biosciences is testing its MB-105 cell therapy in a Phase 2 clinical trial for people with difficult-to-treat cancer. Photo via march.bio

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

From Your Site Articles
This year's award recipients span industries and technologies. Photos courtesy

2024 Houston Innovation Awards winners named at annual event

drum roll, please...

Houston innovators — the moment you've been waiting for. The winners of the 2024 Houston Innovation Awards were named at the annual event.

The Houston Innovation Awards honored over 40 finalists across categories, naming the 12 winners and honoring the two Trailblazer Legacy Awards at the event.

The 2024 judges — who represent various industries and verticals in Houston — scored over 200 submissions. The event, hosted at TMC Helix Park on November 14 and emceed by Joey Sanchez, 2023 Ecosystem Builder award recipient and founder of Cup of Joey, revealed the winners.

The event's sponsors included Texas Medical Center, Milam & Greene, EIGHT Beer, Houston Community College, Microsoft, Halliburton Labs, Mercury, Pillsbury Winthrop Shaw Pittman LLP, Rice Innovation & Ion District, Growth Pods, Hunton Andrews Kurth and more.

Without further adieu, here the winners from the 2024 Houston Innovation Awards.

Corrolytics is a technology startup founded to solve microbiologically influenced corrosion problems for industrial assets. Co-founder and CEO Anwar Sadek says he's collected over $1 million in dilutive and non-dilutive funding from grants and other opportunities thanks to help from mentors.

"As a founder, I am always eager to assist and support fellow entrepreneurs, especially those navigating the unique challenges that come with being a BIPOC founder," he says. "With the guidance of mentors, I learned to master the complexities of the application process for grants and other funding opportunities. In turn, I actively share my experiences with other founders, helping them navigate similar paths."

Koda Health is a provider of a tech-enabled care coordination service for improving serious illness care planning. Founder and CEO Tatiana Fofanova says that her company's last fundraise has been one of her biggest career challenges to date.

"In a venture downturn that only cared about artificial intelligence, I closed my second round six days before I gave birth to my son," she says. "Fundraising in enterprise health tech is a tough task on a good year. Fundraising in an AI-obsessed downturn while seven months pregnant was the greatest physical and professional challenge of my life. I was only able to do such a Herculean feat through the support of my husband, my amazing professional network, and the Koda team."

March Biosciences, a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies, was co-founded by CEO Sarah Hein.

"Our therapy has resulted in multiple long-term remissions in patients with advanced T cell lymphoma, which is unheard," Hein says on what sets March apart. "Our drug is simpler, cheaper, and more efficient to produce than any of our competition's approaches. And our company operates with a lean, fit-for-purpose structure that allows us to move faster and more efficiently than industry norms."

Founded by CEO Cindy Taff, Sage Geosystems is an energy company focused on developing and deploying advanced geothermal technologies to provide reliable power and sustainable energy storage solutions regardless of geography.

"Sage Geosystems sets itself apart from competitors with its Geopressured Geothermal Systems, which can be deployed almost anywhere, unlike traditional geothermal technologies that require specific geographic conditions," Taff says. "This flexibility enables Sage to provide a reliable and virtually limitless power supply, making it ideal for energy-intensive applications like data centers."

Venus Aerospace, a deep tech company founded by husband and wife team Sassie and Andrew Duggleby, is developing reusable hypersonic technology for aviation, defense, and beyond. The team says its company culture is what drives its success.

"Traditionally, the aerospace industry tends to burn out its employees with no room for work- life balance. One of our core visions is being 'home for dinner,'" the company reported. "We want to fly you to one side of the world and still have you home for dinner. And if you work for Venus, we expect you to not only get your job done, but prioritize your family and make it home in time for dinner."

Cognitive Space, an automated satellite operations provider that enables constellations to scale, was founded by CEO Guy de Carufel, who worked at NASA for eight years before starting this company.

Cognitive Space, working in defense sector, provides "AI for automating the space infrastructure, from effective ordering across multiple data providers, to optimized scheduling of satellite operations from sensor and link management," de Carufel says. "Addressing complexities in managing heterogeneous space systems at scale."

Cart.com is a unified commerce and logistics solutions provider for B2C and B2B companies is a fast-growing ecommerce platform founded by CEO Omair Tariq.

"In the last 12 months, Cart.com has dramatically grown its fulfillment network’s scale and technological capabilities," writes CEO Omail Tariq in his Houston Innovation Awards application. "We have been laser-focused on improving quality, performance and efficiency at scale while continuing to aggressively grow our customer base, expand our capabilities to customers in new industries and grow our physical presence to new locations. Prioritizing our strategic growth initiatives has been critical in the current macroeconomic environment as profitable growth remains paramount for our team."

Corrolytics, a technology startup founded to solve microbiologically influenced corrosion problems for industrial assets, secured the most votes from the Houston innovation community.

"If I could give myself advice before starting the company, I would say to embrace the challenges early on, as they are invaluable learning opportunities," Co-founder and CEO Anwar Sadek says. "Focus on building a strong network, especially with mentors and industry leaders who can guide you through the unknowns. Lastly, be prepared for the unexpected, stay adaptable, and never underestimate the importance of a clear mission that inspires both your team and your customers."

Impact Hub Houston is a nonprofit that serves as a pivotal hub within the city's innovation ecosystem, fostering a dynamic environment where changemakers, entrepreneurs, and community leaders converge to drive social impact and innovation forward.

"We mobilize problem solvers to use their knowledge, skills and technology to address community challenges, demonstrating our commitment to local impact while also providing a global reach for Houston innovators," says Grace Rodriguez, founder and CEO of the organization. "Our work extends to supporting underrepresented communities, and we work with public and private stakeholders to promote sustainable business practices that prioritize economic development, environmental stewardship and social equity."

Mitra Miller is the vice president of Houston Angel Network, but also founded and chairs Eagle Investors, a nonprofit group teaching students about the investment and innovation community. She serves as an active mentor for many organizations across Houston.

"Houston has the most friendly, open, collaborative, and inclusive innovation environment anywhere," Miller says. "When I ask individuals and organizations to partner on events and initiatives, they readily agree and give freely of their time and resources. There is a generosity of spirit that is very special to Houston."

Juliana Garaizar, founding partner of Energy Tech Nexus, invests with groups — such as Portfolia, Houston Angel Network, Business Angel Minority Association, and more — locally and beyond.

"I'm a hands on investor," she says. "I offer mentorship and industry and other investor connections. I take advisory roles and board observer seats."

Phillip Yates is the founder and CEO of Equiliberty Inc., but wears a few other hats too. In 2011, he helped establish a pre-venture business incubator at the Houston Area Urban League Entrepreneurship Center. He served as general counsel for the Business Angel Minority Association and Direct Digital Holdings Inc., and currently serves as chairman of Impact Hub Houston.

"My favorite part of Houston's innovative ecosystem is the growing network of resources for founders," he says. "Given our racial, ethnic and culturally diverse population, we have a wider range of experiences and perspectives — and ideas that lead to better problem solving, creative solutions and understanding of the needs our community."

This year, the Houston innovation community suffered the loss of two business leaders who left a significant impact on the ecosystem. Both individuals' careers were recognized with Trailblazer Legacy Awards.

Paul Frison, founder of the Houston Technology Center, and Scott Gale, executive director of Halliburton Labs, received the award posthumously. Frison died on September 5, and Gale died on September 24. The award was decided on by the 2024 judges and InnovationMap.

“I am immensely proud to honor these two remarkable individuals with the Trailblazer Award this year. It is fitting, as they represent two generations of building Houston’s ecosystem," 2023 Trailblazer Award recipient Brad Burke, managing director of the Rice Alliance and the associate vice president for industry and new ventures within Rice University's Office of Innovation, tells InnovationMap.

"Paul Frison was a pioneering leader who helped establish the Houston Technology Center and fostered the city’s tech ecosystem during the initial technology boom around the year 2000. Scott Gale, through his work at Halliburton Labs over the past five years, has been instrumental in launching Houston’s energy transition ecosystem," he continues. "Both have played pivotal roles in championing technology innovators.” Continue reading.

This week's roundup of Houston innovators includes Bryton Praslicka of FluxWorks, Sarah Hein of March Biosciences, Jerin Varkey of Offer Approved. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three founders across therapeutics, space, and sports tech.

Bryton Praslicka, CEO and founder of FluxWorks

FluxWorks, a hardtech startup, opened its new home-base in Conroe, Texas. Photo courtesy FluxWorks

FluxWorks, a hardtech startup, recently opened its new base of operations in Workhub Developments’ Conroe location.

Founded in College Station by CEO Bryton Praslicka, FluxWorks specializes in making contactless magnetic gears for use in extreme conditions. At 9,000 square feet, the new Conroe facility is a result of discussions with Governor Greg Abbott's office and the Greater Houston Partnership, who introduced the company’s leadership to the Conroe Economic Development Council, encouraging their move, Praslicka tells InnovationMap.

“The pieces of the puzzle were all there, and with the support of the local, state, and federal government, we were thrilled to move to Conroe,” Paslicka says. Read more.

Sarah Hein, co-founder and CEO of March Biosciences

Sarah Hein joins the Houston Innovators Podcast to discuss how the company will use its series A funding. Photo via march.bio

When cancer originates in a patient, their body fights as hard as it can against the disease, but sometimes, the cancer wins the battle. However, one Houston cell therapy startup is working on an artillery of therapeutics to help arm patients' bodies to win the war.

Founded in 2022, March Biosciences is a cell therapy company born in part out of the Texas Medical Center's Accelerator for Cancer Therapeutics, where Sarah Hein served as inaugural entrepreneur in residence. In that role, she met her co-founders Max Mamonkin and Malcolm Brenner.

Now, leading the startup as CEO, Hein tells the Houston Innovators Podcast that with March's lead product, MB-105, an autologous CD5 CAR T cell therapy, the name of the game is to zero in on advancing this particular treatment to its phase II trial next year.

"Targeted therapies are targeted. Our target is expressed on these T-cell cancers, and there are a couple other cancers, like Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia," Hein says on the show. "Unfortunately, I don't think there's ever going to be a magic bullet that is going to hit a huge swath of these cancers. We're going to continue to chip away at these cancers by creating really elegantly engineered therapies against these different kinds of tumors.

"March, in general, is committed to this idea that we're going to continue to work on difficult tumors and different targets with our uniquely engineered targeting strategy against these diseases. As we expand into the next year, you'll see us speak on this a little more on how we're going to continue to work on new diseases that havent been addressed previously," she continues. Read more.

Jerin Varkey, founder and CEO of Offer Approved

Looking to score the best deal on your next game ticket? A new Houston-founded app promises to revolutionize the resale market. Photo via LinkedIn

Online platforms have long simplified the process of buying, selling, and trading event tickets. But what happens when your tickets don’t sell or when you’re stuck with costly season tickets you can’t use? You might end up giving them away or leaving them unused, leading to a financial loss either way.

This is the challenge that Houstonian Jerin Varkey is willing to address with Offer Approved, a new platform that empowers sellers and buyers, guaranteeing that no seat goes unused.

The idea took root around two years ago when Varkey, a passionate sports fan and season ticket holder, faced a new challenge. After becoming a parent, he found himself unable to attend every game. Frustrated with traditional resale platforms, he quickly realized that high fees and limited time made it difficult to sell all his tickets, causing him to lose money each time.

"I knew there was someone out there willing to pay $50," he recalls. Read more.

Sarah Hein, co-founder and CEO of March Biosciences, joins the Houston Innovators Podcast to discuss how the company will use its series A funding. Photo via march.bio

With fresh funding, Houston cancer-fighting cell therapy gears up for continued clinical trials

Houston innovators podcast episode 259

When cancer originates in a patient, their body fights as hard as it can against the disease, but sometimes, the cancer wins the battle. However, one Houston cell therapy startup is working on an artillery of therapeutics to help arm patients' bodies to win the war.

Founded in 2022, March Biosciences is a cell therapy company born in part out of the Texas Medical Center's Accelerator for Cancer Therapeutics, where Sarah Hein served as inaugural entrepreneur in residence. In that role, she met her co-founders Max Mamonkin and Malcolm Brenner.

Now, leading the startup as CEO, Hein tells the Houston Innovators Podcast that with March's lead product, MB-105, an autologous CD5 CAR T cell therapy, the name of the game is to zero in on advancing this particular treatment to its phase II trial next year.

"Targeted therapies are targeted. Our target is expressed on these T-cell cancers, and there are a couple other cancers, like Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia," Hein says on the show. "Unfortunately, I don't think there's ever going to be a magic bullet that is going to hit a huge swath of these cancers. We're going to continue to chip away at these cancers by creating really elegantly engineered therapies against these different kinds of tumors.

"March, in general, is committed to this idea that we're going to continue to work on difficult tumors and different targets with our uniquely engineered targeting strategy against these diseases. As we expand into the next year, you'll see us speak on this a little more on how we're going to continue to work on new diseases that havent been addressed previously," she continues.

Hein explains how March Biosciences — named in part as a nod to one of Houston's best months weather wise — has benefitted from the support of the local life science community. Last year, March announced its partnership with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. Hein says over the past year, they've moved into CTMC and that's allowed them to accelerate their progress as a company.

"Houston has a unique sophistication in cell therapy. Where we've had biotech spinout, cell therapy has been one of our more successful verticals," she says. "We've had resources and knowledge here that were uniquely available for our drug category."

Earlier this month, March Biosciences announced an oversubscribed $28.4 million series A led by Mission BioCapital and 4BIO Capital and bringing the company's total funding secured to more than $51 million, including its prestigious CPRIT grant. Hein says this funding will go toward further developing March's therapeutics and team as it gears up for its phase II trial next year.

Ultimately, Hein explains on the show how passionate she is and her team is on continuing to develop treatments to fight cancer with their targeted approach.

"I never have to explain to people why we would go out and fight cancer. I think it's a self-evident hypothesis," she says. "But what I personally find is exciting in cancer therapies in general are these immune therapies, where you using the body's own immune system to seek out and destroy the cancer cells.

"What's really exciting about that is these are the same immune cells that fight cancer or pre-cancers for most of your life and usually what happens is the cancers figure out a way to mass themselves. With modern approaches, we can boost the immune system."

This week's roundup of Houston innovators includes Sarah Hein of March Biosciences, Sean Kelly of Amperon, Donnell Debnam Jr. of the Google in Residence program, and the 2023 Houston Innovation Awards judges. Photos courtesy

3+ Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries, from biotech to energy software, recently making headlines in Houston innovation — plus the decision makers for the Houston Innovation Awards.

Sarah Hein, CEO and co-founder of March Biosciences

Early-stage cell therapy startup March Biosciences has partnered with CTMC. Photo via march.bio

Named in part after one of the best months out of the year for Houstonians, March Biosciences has entered into a uniquely Houston partnership. Sarah Hein, CEO and co-founder of the cancer immunotherapy startup, met her co-founders at the TMC Accelerator for Cancer Therapeutics.

“It's a perfect example of the opportunities here in Houston where you can go from bench to bedside, essentially, in the same institution. And Baylor has been particularly good at that because of the Center for Cell and Gene Therapy,” says Hein.

The company recently announced a partnership with another Houston institution, CTMC. Read more.

Sean Kelly, CEO and co-founder of Amperon

It's payday for a startup that's improving analytics for its energy customers. Photo via Getty Images

Amperon Holdings Inc. raised $20 million in its latest round of funding in order to accelerate its energy analytics and grid decarbonization technology.

The fresh funding will support the company in evolving its platform that conducts electricity demand forecasting to a comprehensive data analytics solution.

“The energy transition is creating unprecedented market volatility, and Amperon is uniquely positioned to help market participants better navigate the transitioning grid – both in the U.S. and as we expand globally,” Sean Kelly, CEO and co-founder of Amperon, says. Read more.

Donnell Debnam Jr., instructor in the Google in Residence program

Thanks to Google, Donnell Debnam Jr. is helping train future software engineers at Prairie View A&M University. Photo via LinkedIn

Computer science students at Prairie View A&M University are gaining firsthand knowledge this semester from a Google software engineer.

As an instructor in the Google in Residence program, Donnell Debnam Jr. is helping train future software engineers — and other potential tech professionals — who are enrolled this fall in Prairie View A&M’s introductory computer science course. Fifty-four students are taking the class.

“I participated in the Google in Residence program as a student, and I am honored to return as an instructor,” says Debnam. “This innovative program was created to support greater diversity in the tech industry, and as an instructor, I have the privilege of helping the next generation of software engineers create a more inclusive culture within the STEM fields.” Read more.

2023 Houston Innovation Awards judges

Bonus innovators to know: The 10 Houstonians deciding the finalists and winners for this year's Houston Innovation Awards. Photos courtesy

Ten Houstonians are in the hot seat for deciding the best companies and individuals in Houston's innovation ecosystem.

InnovationMap has announced its 2023 Houston Innovation Awards judging panel, which includes startup founders, nonprofit leaders, investors, corporate innovators, and more.

Meet the 10 selected judges who will evaluate applications from the nearly 400 nominations that were submitted this year. Read more.

Early-stage cell therapy startup March Biosciences has partnered with CTMC. Photo via march.bio

Cancer-fighting startup partners with Houston cell therapy accelerator

marching on

When it came time to name their cell therapy startup, Houston life science innovators simply had to look to their calendar.

“I would argue that March is the best month in Houston,” Sarah Hein tells InnovationMap. “We started talking about putting this company together during COVID, so we were outside a lot. And we actually got together in March.”

That’s why the CEO and her co-founders Max Mamonkin and Malcolm Brenner decided to name their company March Biosciences.

It's a fresh, unstuffy name for a startup that has an innovative take on cancer immunotherapy. Their lead asset is an advanced cellular therapy known as MB-105, an autologous CD5 CAR T cell therapy. For patients with T-cell lymphoma and leukemia who have failed all currently available lines of therapy, the prognosis is understandably extremely poor. But in a phase one study, MB-105 has been proven to safely treat those patients. The phase two study is expected to begin in the first half of 2024.

Hein met Mamonkin at the TMC Accelerator for Cancer Therapeutics (ACT), at which the alumna of Resonant Therapeutics and Courier Therapeutics was an entrepreneur in residence.

“It's a perfect example of the opportunities here in Houston where you can go from bench to bedside, essentially, in the same institution. And Baylor has been particularly good at that because of the Center for Cell and Gene Therapy,” says Hein.

The serial entrepreneur first came to Houston as a PhD student in molecular and cellular biology at Baylor College of Medicine, but during her studies she became excited by the startup ecosystem in her new hometown. After earning her degree, she became a venture fellow at the Mercury Fund. Her experience in both science and business made her an ideal candidate to take March Biosciences to the next level.

In September, the company announced that it formed a strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience.

“Our unique risk-sharing model allows us to collaborate with organizations like March Biosciences to accelerate the development and manufacture of innovative cell therapies, like MB-105, and bring them into the clinic with a consistent and scalable manufacturing process,” said CTMC’s CEO, Jason Bock in a press release.

The partnership “has allowed us to move really quickly,” Hein says.

That’s because what CTMC does uniquely well is take early stage companies like March Biosciences and advance them to a state that’s ready for manufacturing in a short time, around 18 months, says Hein.

According to Hein, March Biosciences’ success is a testament to Houston and its world-class medical center.

“It’s a great example of the opportunities you see here in Houston, where we have a technology that was developed by brilliant scientists here in Houston and we can pull together the resources that we need to take it to the next level,” Hein says. "Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.

View All Listings